ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process (2020)
Source: Frontiers in Endocrinology. Unidade: ICB
Subjects: BIOLOGIA CELULAR, INSULINA, DIABETES MELLITUS, CAMUNDONGOS, CÁLCIO, GLICOSE, METABOLISMO ENERGÉTICO, MODELOS ANIMAIS DE DOENÇAS
ABNT
FERREIRA, Sandra M. et al. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process. Frontiers in Endocrinology, v. 11, p. 9 , 2020Tradução . . Disponível em: https://doi.org/10.3389/fendo.2020.599165. Acesso em: 02 maio 2024.APA
Ferreira, S. M., Costa Júnior, J. M., Kurauti, M. A., Leite, N. C., Ortis, F., Rezende, L. F., et al. (2020). ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process. Frontiers in Endocrinology, 11, 9 . doi:10.3389/fendo.2020.599165NLM
Ferreira SM, Costa Júnior JM, Kurauti MA, Leite NC, Ortis F, Rezende LF, Barbosa HC, Boschero AC, Santos GJ. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process [Internet]. Frontiers in Endocrinology. 2020 ; 11 9 .[citado 2024 maio 02 ] Available from: https://doi.org/10.3389/fendo.2020.599165Vancouver
Ferreira SM, Costa Júnior JM, Kurauti MA, Leite NC, Ortis F, Rezende LF, Barbosa HC, Boschero AC, Santos GJ. ARHGAP21 acts as an inhibitor of the glucose-stimulated insulin secretion process [Internet]. Frontiers in Endocrinology. 2020 ; 11 9 .[citado 2024 maio 02 ] Available from: https://doi.org/10.3389/fendo.2020.599165